Cytodyn Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 14

Employees

  • Stock Symbol
  • CYDY

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $0.22
  • (As of Friday Closing)

Cytodyn General Information

Description

CytoDyn Inc is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of its product candidate, leronlimab, which is being studied for its potential in solid-tumor oncology. Leronlimab targets CCR5, a receptor increasingly recognized for its role in tumor progression, metastasis and immune regulation, providing the company with the opportunity to explore a potentially differentiated therapeutic approach across multiple solid tumor indications. It operates as a single reporting segment, focused on the clinical development of leronlimab.

Contact Information

Website
www.cytodyn.com
Formerly Known As
Rexray
Ownership Status
Publicly Held
Financing Status
Formerly Angel backed
Corporate Office
  • 1111 Main Street
  • Suite 660
  • Vancouver, WA 98660
  • United States
+1 (360)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
OTCM
Vertical(s)
Corporate Office
  • 1111 Main Street
  • Suite 660
  • Vancouver, WA 98660
  • United States
+1 (360)

Cytodyn Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytodyn Stock Performance

As of 20-Nov-2026, Cytodyn’s stock price is $0.22. Its current market cap is $326M with 1.47B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.22 $0.23 $0.18 - $0.40 $326M 1.47B 1.97M -$0.03

Cytodyn Financials Summary

As of 31-Aug-2026, Cytodyn has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Aug-2026 FY 2026 31-May-2026 FY 2025 31-May-2025 FY 2024 31-May-2024
EV 342,530 426,608 432,409 185,796
Revenue 0 0 0 0
EBITDA (54,998) (40,450) 8,029 (44,294)
Net Income (57,095) (42,699) 3,745 (49,841)
Total Assets 19,054 13,973 18,047 11,136
Total Debt 27,270 27,276 27,341 30,076
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cytodyn Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cytodyn‘s full profile, request access.

Request a free trial

Cytodyn Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CytoDyn Inc is a clinical-stage biotechnology company focused on the clinical development and potential commercializatio
Drug Discovery
Vancouver, WA
14 As of 2026

Wilmington, DE
 

San Diego, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cytodyn Competitors (21)

One of Cytodyn’s 21 competitors is Ayala Pharmaceuticals, a Corporation company based in Wilmington, DE.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ayala Pharmaceuticals Corporation Wilmington, DE
iBio Corporation San Diego, CA
Dynavax Technologies Formerly VC-backed Emeryville, CA
GeoVax Labs Corporation Smyrna, GA
VLPbio Formerly VC-backed Boecillo, Spain
You’re viewing 5 of 21 competitors. Get the full list »

Cytodyn Patents

Cytodyn Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026198581-A1 Compositions and methods of treating ccr5 positive cancers and immune exhaustion Pending 17-Mar-2025
WO-2025250666-A1 Methods of treating cancer and inflammation-related diseases with leronlimab Pending 29-May-2024
US-20240392014-A1 Aav-mediated expression of long-acting anti-ccr5 binding agents for the treatment and prevention of hiv Pending 02-Dec-2022
US-20240392015-A1 Long-acting anti-ccr5 binding agents for the prevention and treatment of hiv Pending 02-Dec-2022
AU-2023288452-A1 Methods of treating nafld and nash Pending 22-Jun-2022 A61P1/16
To view Cytodyn’s complete patent history, request access »

Cytodyn Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytodyn Investments & Acquisitions (4)

Cytodyn’s most recent deal was a Merger/Acquisition with ProstaGene for . The deal was made on 16-Nov-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ProstaGene 16-Nov-2018 Merger/Acquisition Diagnostic Equipment
Progenics Pharmaceuticals (Pro 140) 30-Jul-2012 Corporate Asset Purchase Buildings and Property
Advanced Genetic Technologies 30-Jan-2007 Merger/Acquisition Drug Discovery
Advanced Influenza Technologies 21-Jul-2006 Merger/Acquisition Drug Discovery
To view Cytodyn’s complete investments and acquisitions history, request access »

Cytodyn ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Cytodyn’s complete esg history, request access »

Cytodyn FAQs

  • When was Cytodyn founded?

    Cytodyn was founded in 2002.

  • Where is Cytodyn headquartered?

    Cytodyn is headquartered in Vancouver, WA.

  • What is the size of Cytodyn?

    Cytodyn has 14 total employees.

  • What industry is Cytodyn in?

    Cytodyn’s primary industry is Drug Discovery.

  • Is Cytodyn a private or public company?

    Cytodyn is a Public company.

  • What is Cytodyn’s stock symbol?

    The ticker symbol for Cytodyn is CYDY.

  • What is the current stock price of Cytodyn?

    As of 20-Nov-2026 the stock price of Cytodyn is $0.22.

  • What is the current market cap of Cytodyn?

    The current market capitalization of Cytodyn is $326M.

  • Who are Cytodyn’s competitors?

    Ayala Pharmaceuticals, iBio, Dynavax Technologies, GeoVax Labs, and VLPbio are some of the 21 competitors of Cytodyn.

  • What is Cytodyn’s annual earnings per share (EPS)?

    Cytodyn’s EPS for 12 months was -$0.03.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process